

Johnson & Johnson Innovation

Jeanne Bolger

Vice President, Venture Investments


December, 2015




Johnson & Johnson

A Global Leader in Healthcare


Sales \$74.3 Billion



20%




37%



43%

Innovation is everywhere, but mostly outside of our own organization



London Team

Satellites: Israel & Russia

One Chapel Place
London W1G 0BG
<http://www.jnjinnovation.com/>



THERAPEUTIC AREA LEADS

Immunology

Oncology

CV
Metabolic

Neuroscience

Microbiome
/Vaccines

Infectious
Disease

Consumer

MDD

- ✓ JJDC/Investor
- ✓ Platform Technologies/Incubators
- ✓ Transactions
- ✓ Alliance Management
- ✓ Discovery Sciences
- ✓ Legal Affairs

- ✓ New Ventures
- ✓ External Innovation, Russia, Nordics and Switzerland
- ✓ Diagnostics
- ✓ Project Management
- ✓ Information Technology
- ✓ Communication & External Affairs
- ✓ Finance

Innovation Centre Themes

Sustaining our position as a leading global health care company requires continuous access to the best science and technology

- To be a “partner of choice” and deliver more value, we organized our external innovation model around three themes:


1. *Capture more value by moving **earlier** in the innovation chain*
2. *A critical mass of **scientific experts** and **deal-making support** located in close proximity to sources of innovation*
3. ***Simplified access** and improvement of our ability to **effectively execute early deals***



Aligned with business strategies to become the long term value driver for our organization

Co-creation Model

J&J Innovation providing access to...



Advancing innovative **products** by enabling access to a full range of incubation 'ingredients' supplied by network of strategic partners

Areas of Interest

Well-being & beauty

Baby care
Body care
Facial skin care
Sun care
Feminine personal care

Health & Healing

Allergy care
Compromised skin
Cough & cold care
Digestive health
Oral care
Pain care

Consumer

Cardiovascular & Metabolism
Immunology
Infectious Diseases & Vaccines
Neuroscience
Oncology

Pharmaceuticals

General Surgery
Biosurgery
Orthopedics
Vision Care
Infection Care
Diabetes
Energy
Cardiovascular
Ear, Nose, Throat
Neuroscience
Aesthetics

Med Devices

Success Factors




- Willingness to give up control
- Willingness to share reward
- Skin in the game
- Closeness to the partnership
- Personal accountability
- Ability to adapt and act
- Willingness to innovate / embrace change

Exploring new pathways to develop first-in-class small molecule therapies in immune-mediated diseases

Catalyzing innovation through expert networks

Investigating the role of IL-15 – a protein that is crucial to immune function – in the treatment of autoimmune diseases such as psoriasis, rheumatoid arthritis and inflammatory bowel disease.



- › Project leadership
- › Lead identification – HTS (Discovery Sci.)
- › PPI know how
- › Medicinal Chemistry – TA guided CRO



- › IL-15 Know how and IP
- › Tools and assays
- › Early NCE hits




- › Scientific rationale for IL-15 antagonists
- › PsO, RA, IBD expertise
- › Tools and assays
- › Patient access
- › Translational expertise

Accelerating the translation of scientific breakthroughs through an “asset-centric” approach

A close collaboration between academia, venture capital and industry helped accelerate ichorcumab’s development path

- Ichorcumab is a recombinant human antibody developed by XO1 to mimic the activity of a human antibody which appears to produce an anticoagulated state without predisposition to bleeding.
- The acquisition illustrates how our global innovation strategy enables a local, hands-on approach that supports the regional life science ecosystems, provides Janssen a window on the most exciting science around the world and provides access to potentially breakthrough products in areas of strategic interest



Can anti-inflammatory interventions hold therapeutic benefits for people living with brain disorders?

A high unmet medical need called for an innovative approach

- A UK-wide consortium of neuroscience experts, collaborating to investigate the impact of anti-inflammatory interventions in depression and Alzheimer's disease.
- Over five years, the group will combine expertise and resources to carry out a number of initiatives such as bioinformatics studies and preclinical and clinical studies to identify biomarkers designed to identify appropriate molecules to bring forward for clinical testing and to identify patients subgroups.

COMMERCIAL PARTNERS

- › Financial support
- › Drug discovery expertise
- › Preclinical models
- › Imaging expertise
- › Access to anti-inflammatory drugs



ACADEMIC PARTNERS

- › Neuroimaging expertise
- › Clinical phenotyping and trials
- › Preclinical models
- › Informatics



Johnson & Johnson Innovation-Karolinska Institutet collaboration

Launched 22 May 2015

A broad and unique industry-academia collaboration in the Nordic region to **advance medical research**, nurture **emerging healthcare companies**, accelerate the **development of breakthrough products** for improved **treatment outcomes**. To support the collaboration Johnson & Johnson Innovation opened the **life science innovation office** at Karolinska Institutet.

Johnson & Johnson INNOVATION

Commercial knowledge
Resources
Coaching
Investment
Seed-financing



Innovation focus (KI Innovations AB)
Abundance of early-stage science
World class life sciences research
Nordic influence

A great idea can come
from anywhere



Make the connection

Johnson & Johnson INNOVATION